Ultragenyx Pharmaceutical Inc.
RARE
Market Cap$2.89B
Close$
$55.30
76.8% upside
Current Fair Value
76.8% upsideUndervalued by 76.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.89 Billion |
|---|---|
| Enterprise Value | $3.58 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.29 |
| Beta | 0.25 |
| Outstanding Shares | 98,460,445 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.54 |
|---|---|
| PEG | 43.76 |
| Price to Sales | 5.21 |
| Price to Book Ratio | 31.28 |
| Enterprise Value to Revenue | 5.88 |
| Enterprise Value to EBIT | -7.26 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 5.84 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis